JP2024521696A5 - - Google Patents
Info
- Publication number
- JP2024521696A5 JP2024521696A5 JP2023571764A JP2023571764A JP2024521696A5 JP 2024521696 A5 JP2024521696 A5 JP 2024521696A5 JP 2023571764 A JP2023571764 A JP 2023571764A JP 2023571764 A JP2023571764 A JP 2023571764A JP 2024521696 A5 JP2024521696 A5 JP 2024521696A5
- Authority
- JP
- Japan
- Prior art keywords
- egfr
- subject
- seq
- administered
- bispecific anti
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163190004P | 2021-05-18 | 2021-05-18 | |
| US63/190,004 | 2021-05-18 | ||
| PCT/IB2022/054628 WO2022243900A1 (en) | 2021-05-18 | 2022-05-18 | Methods for identifying cancer patients for combination treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024521696A JP2024521696A (ja) | 2024-06-04 |
| JP2024521696A5 true JP2024521696A5 (enExample) | 2025-05-19 |
Family
ID=81927585
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023571764A Withdrawn JP2024521696A (ja) | 2021-05-18 | 2022-05-18 | 併用治療のためのがん患者を同定するための方法 |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20220372581A1 (enExample) |
| EP (1) | EP4341440A1 (enExample) |
| JP (1) | JP2024521696A (enExample) |
| KR (1) | KR20240007758A (enExample) |
| CN (1) | CN117716050A (enExample) |
| AU (1) | AU2022276181A1 (enExample) |
| BR (1) | BR112023024079A2 (enExample) |
| CA (1) | CA3220465A1 (enExample) |
| MX (1) | MX2023013784A (enExample) |
| TW (1) | TW202309094A (enExample) |
| WO (1) | WO2022243900A1 (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021010265A (es) * | 2019-02-26 | 2021-09-23 | Janssen Biotech Inc | Terapias de combinacion y estratificacion de pacientes con anticuerpos anti-egfr/c-met biespecificos. |
| CN120131659B (zh) * | 2025-05-09 | 2025-10-28 | 中国医学科学院基础医学研究所 | Mobocertinib与抗PD-1抗体联合应用治疗癌症的方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0281604B1 (en) | 1986-09-02 | 1993-03-31 | Enzon Labs Inc. | Single polypeptide chain binding molecules |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| ATE199392T1 (de) | 1992-12-04 | 2001-03-15 | Medical Res Council | Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung |
| AUPO591797A0 (en) | 1997-03-27 | 1997-04-24 | Commonwealth Scientific And Industrial Research Organisation | High avidity polyvalent and polyspecific reagents |
| AU2005250484B2 (en) | 2004-06-04 | 2011-08-11 | Genentech, Inc. | EGFR mutations |
| WO2006028936A2 (en) | 2004-09-02 | 2006-03-16 | Genentech, Inc. | Heteromultimeric molecules |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| DE102005028778A1 (de) | 2005-06-22 | 2006-12-28 | SUNJÜT Deutschland GmbH | Mehrlagige Folie mit einer Barriere- und einer antistatischen Lage |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| WO2007147901A1 (en) | 2006-06-22 | 2007-12-27 | Novo Nordisk A/S | Production of bispecific antibodies |
| CN101952312A (zh) | 2007-07-31 | 2011-01-19 | 米迪缪尼有限公司 | 多特异性表位结合蛋白及其应用 |
| US20090162359A1 (en) | 2007-12-21 | 2009-06-25 | Christian Klein | Bivalent, bispecific antibodies |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| US9266967B2 (en) | 2007-12-21 | 2016-02-23 | Hoffmann-La Roche, Inc. | Bivalent, bispecific antibodies |
| US8242247B2 (en) | 2007-12-21 | 2012-08-14 | Hoffmann-La Roche Inc. | Bivalent, bispecific antibodies |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| SG10201408229WA (en) * | 2010-08-31 | 2015-02-27 | Genentech Inc | Biomarkers and methods of treatment |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| US9574010B2 (en) | 2011-11-04 | 2017-02-21 | Zymeworks Inc. | Stable heterodimeric antibody design with mutations in the Fc domain |
| KR102373193B1 (ko) * | 2012-11-21 | 2022-03-10 | 얀센 바이오테크 인코포레이티드 | 이중특이성 EGFR/c-Met 항체 |
| AU2013355260B2 (en) * | 2012-12-04 | 2019-07-25 | Caris Mpi, Inc. | Molecular profiling for cancer |
| CN105102635B (zh) * | 2013-03-15 | 2020-09-25 | 生命技术公司 | 肺癌的分类和可行性指数 |
| US20200157563A1 (en) * | 2017-07-18 | 2020-05-21 | The Broad Institute, Inc. | Methods of producing human cancer cell models and methods of use |
-
2022
- 2022-05-17 TW TW111118423A patent/TW202309094A/zh unknown
- 2022-05-18 WO PCT/IB2022/054628 patent/WO2022243900A1/en not_active Ceased
- 2022-05-18 KR KR1020237043058A patent/KR20240007758A/ko not_active Withdrawn
- 2022-05-18 US US17/747,346 patent/US20220372581A1/en not_active Abandoned
- 2022-05-18 EP EP22727440.4A patent/EP4341440A1/en not_active Withdrawn
- 2022-05-18 MX MX2023013784A patent/MX2023013784A/es unknown
- 2022-05-18 AU AU2022276181A patent/AU2022276181A1/en not_active Abandoned
- 2022-05-18 BR BR112023024079A patent/BR112023024079A2/pt unknown
- 2022-05-18 CA CA3220465A patent/CA3220465A1/en active Pending
- 2022-05-18 JP JP2023571764A patent/JP2024521696A/ja not_active Withdrawn
- 2022-05-18 CN CN202280050684.9A patent/CN117716050A/zh active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Dziadziuszko et al. | Afatinib in NSCLC with HER2 mutations: results of the prospective, open-label phase II NICHE trial of European Thoracic Oncology Platform (ETOP) | |
| Tan et al. | Next-generation epidermal growth factor receptor tyrosine kinase inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer | |
| KR102714702B1 (ko) | 항-pd-1 항체를 사용하여 종양을 치료하는 방법 | |
| CN111032082B (zh) | Her2阳性癌症的治疗 | |
| JP2022521610A5 (enExample) | ||
| US20150231238A1 (en) | Overcoming resistance to erbb pathway inhibitors | |
| CN110325191A (zh) | 以较少的副作用治疗egfr-驱动的癌症 | |
| US20190175731A1 (en) | Use of glutamate modulating agents with immunotherapies to treat cancer | |
| US11845994B2 (en) | Response to EGFR blockade | |
| US8426418B2 (en) | Method to treat melanoma in BRAF inhibitor-resistant subjects | |
| TW201032796A (en) | Treatment of lung cancer with a PARP inhibitor in combination with a growth factor inhibitor | |
| McPherson et al. | A phase 2 trial of buparlisib in patients with platinum‐resistant metastatic urothelial carcinoma | |
| CN112912403A (zh) | 治疗肿瘤的方法 | |
| JP6410795B2 (ja) | カルボキシアミドトリアゾールオロテートを使用する、先の化学療法薬および標的薬物に対する獲得耐性を持つ癌を治療するための方法および組成物 | |
| Kim et al. | Pembrolizumab plus mFOLFOX7 or FOLFIRI for microsatellite stable/mismatch repair-proficient metastatic colorectal cancer: KEYNOTE-651 cohorts B and D | |
| US20190269666A1 (en) | Combination therapy with merestinib and anti-pd-l1 or anti-pd-1 inhibitors for use in the treatment of cancer | |
| CN103717616A (zh) | 表皮生长因子受体基因中的突变 | |
| CN117561062A (zh) | 使用贝伐拉非尼和考比替尼或使用贝伐拉非尼、考比替尼和阿特珠单抗的组合疗法 | |
| Spicer et al. | A phase II study of neoadjuvant opnurasib KRAS G12C inhibitor in patients with surgically resectable non-small cell lung cancer (CCTG IND. 242A): a substudy of the IND. 242 platform master protocol | |
| Kim et al. | An open-label, phase IB/II study of abemaciclib with paclitaxel for tumors with CDK4/6 pathway genomic alterations | |
| JP2023523450A5 (enExample) | ||
| WO2023159066A1 (en) | Use of niraparib for the treatment of brain cancer | |
| TW202320790A (zh) | 治療癌症之方法 | |
| RU2023132992A (ru) | Способы выявления пациентов с онкологическими заболеваниями для комбинированного лечения | |
| US20260116962A1 (en) | Plk1 inhibitor in combination with anti-angiogenics for treating metastatic cancer |